A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
Study sponsor: Kardigan, Inc. · KARD
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-09Estimated
Enrollment · participants332Estimated
Source updated2026-11-04Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.